HomeCompareAADI vs EPRT

AADI vs EPRT: Dividend Comparison 2026

AADI yields 97.56% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AADI wins by $3.46M in total portfolio value
10 years
AADI
AADI
● Live price
97.56%
Share price
$2.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.52M
Annual income
$1,168,366.03
Full AADI calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — AADI vs EPRT

📍 AADI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAADIEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AADI + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AADI pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AADI
Annual income on $10K today (after 15% tax)
$8,292.68/yr
After 10yr DRIP, annual income (after tax)
$993,111.13/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, AADI beats the other by $981,915.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AADI + EPRT for your $10,000?

AADI: 50%EPRT: 50%
100% EPRT50/50100% AADI
Portfolio after 10yr
$1.79M
Annual income
$590,768.44/yr
Blended yield
32.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

AADI
Analyst Ratings
3
Buy
3
Hold
Consensus: Buy
Price Target
$1.63
-20.5% upside vs current
Range: $1.50 — $1.75
Altman Z
1.2
Piotroski
2/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AADI buys
0
EPRT buys
0
No recent congressional trades found for AADI or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAADIEPRT
Forward yield97.56%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$3.52M$64.3K
Annual income after 10y$1,168,366.03$13,170.85
Total dividends collected$3.14M$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$1.63$35.50

Year-by-year: AADI vs EPRT ($10,000, DRIP)

YearAADI PortfolioAADI Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$20,456$9,756.10$11,212$512.01+$9.2KAADI
2$40,540$18,651.56$12,689$692.09+$27.9KAADI
3$77,923$34,545.21$14,521$944.30+$63.4KAADI
4$145,434$62,056.61$16,841$1,302.88+$128.6KAADI
5$263,859$108,244.60$19,841$1,821.64+$244.0KAADI
6$465,868$183,539.14$23,818$2,587.47+$442.1KAADI
7$801,335$302,856.10$29,230$3,744.65+$772.1KAADI
8$1,344,288$486,859.57$36,816$5,540.38+$1.31MAADI
9$2,201,693$763,305.13$47,806$8,413.17+$2.15MAADI
10$3,524,178$1,168,366.03$64,324$13,170.85+$3.46MAADI

AADI vs EPRT: Complete Analysis 2026

AADIStock

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Full AADI Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this AADI vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AADI vs SCHDAADI vs JEPIAADI vs OAADI vs KOAADI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.